Case Reports:

Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report

Shreya Bhatia, Manuel G. Cortez, Spencer Lessans and Wade T. Iams _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:27-30. https://doi.org/10.18632/oncotarget.28550

Metrics: PDF 225 views  |   Full Text 1036 views  |   ?  


Shreya Bhatia1, Manuel G. Cortez1, Spencer Lessans1 and Wade T. Iams1

1 Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA

Correspondence to:

Wade T. Iams, email: [email protected]

Keywords: EGFR mutation; leptomeningeal disease; non-small cell lung cancer; osimertinib

Received: December 14, 2023     Accepted: December 28, 2023     Published: January 16, 2024

Copyright: © 2024 Bhatia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Osimertinib has been shown to be effective for patients with non-small cell lung cancer (NSCLC) with activating EGFR mutations, and these patients are at risk for leptomeningeal disease. In this report, we present a patient of East Asian descent whose initial presentation included severe, progressive leptomeningeal carcinomatosis and a small lung mass, with limited tissue available for molecular testing. She responded to empiric, urgent initiation of osimertinib, repeat tissue sampling revealed an EGFR L858R mutation, and she has experienced durable disease improvement for 18 months on osimertinib monotherapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28550